SEVALENT
DEAD

Serial Number

97583886

Owner

Bexson Biomedical, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Sep 8, 2022

Add to watchlist:

No watchlists yet
View on USPTO

SEVALENT Trademark

Serial Number: 97583886

SEVALENT is a trademark filed by Bexson Biomedical, Inc. on September 8, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Bexson Biomedical, Inc. (4 trademarks)

856 Chelham Way
Santa Barbara, CA 93108

Entity Type: 03

Trademark Details

Filing Date

September 8, 2022

Registration Date

Not Registered

Published for Opposition

December 17, 2024

Goods & Services

Wearable drug delivery devices sold empty, namely, subcutaneous pumps for the delivery of medication for pain management, reduction and relief, addiction disorders, and mental health illnesses

providing regulatory compliance information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor

providing medical information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor

Pharmaceutical preparations for reducing, managing and relieving pain, treating addiction disorders and treating mental health illnesses; pharmaceutical preparations consisting of ketamine, flumazenil and psychedelics for the treatment of pain, addiction disorders and mental health illnesses; pharmaceutical preparations, namely, medicinal psychoactive psychedelic therapies for the treatment of pain, addiction disorders and mental health illnesses; drug delivery agents in the form of small molecules for the controlled release of therapeutic agents; wearable drug delivery devices, namely, subcutaneous pumps, sold filled with pharmaceutical preparations, for the delivery of medication for pain management, reduction and relief, addiction disorders, and mental health illnesses

Medical and scientific research in the fields of addiction disorders, mental health illnesses, pain management, reduction and relief; developing modular subcutaneous delivery platforms for small molecules for controlled delivery of therapeutic agents; medical and scientific research and development in relation to pharmaceuticals and drug delivery platforms; providing scientific information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor

providing business information, advisory, and consultancy services relating to pharmaceuticals and drug delivery devices therefor

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 16, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 16, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 8, 2025 EXRA
SOU EXTENSION 1 GRANTED
Aug 8, 2025 EX1G
SOU EXTENSION 1 FILED
Aug 7, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 7, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 11, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 19, 2024 CNSA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Jan 11, 2024 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jul 12, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Jul 12, 2023 GNSL
SUSPENSION LETTER WRITTEN
Jul 12, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 11, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 10, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 10, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 22, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 22, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 22, 2023 CNRT
ASSIGNED TO EXAMINER
Jun 22, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 26, 2022 NWOS
NEW APPLICATION ENTERED
Sep 12, 2022 NWAP